Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2020 / N 1

Монтелукаст: опасения нуждаются в доказательствах
О.Н. Бродская, М.А. Макарова, А.С. Белевский

References

1. Lee YJ, Kim CK. Review of montelukast use over the past 20 years and monitoring of its effects. Clinical and Experimental Pediatrics 2020 Feb 5. doi: 10.3345/cep.2019.00325. Online ahead of print.
2. Murphy RC, Hammarström S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proceedings of the National Academy of Sciences of the USA 1979 Sep;76(9):4275-9.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2020. Available from: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf Accessed 2020 Jul 30.
4. Marcello C, Carlo L. Asthma phenotypes: the intriguing selective intervention with Montelukast. Asthma Research and Practice 2016 Aug;2:11.
5. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, Deykin A, DiMango E, Fish JE, Ford JG, Israel E, Kiley J, Kraft M, Lemanske RF Jr, Leone FT, Martin RJ, Pesola GR, Peters S, Sorkness CA, Szefler SJ, Wechsler ME, Fahy JV; National Heart Lung and Blood Institute’s Asthma Clinical Research Network. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. American Journal of Respiratory and Critical Care Medicine 2007 Apr;175(8):783-90.
6. Price D, Popov TA, Bjermer L, Lu S, Petrovic R, Vandormael K, Mehta A, Strus JD, Polos PG, Philip G. Effect of montelukast for treatment of asthma in cigarette smokers. Journal of Allergy and Clinical Immunology 2013 Mar;131(3):763-71.
7. Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma controller agents. The European Respiratory Journal 2006 Apr;27(3):495-503.
8. Sutherland ER, Camargo CA Jr, Busse WW, Meltzer EO, Ortega HG, Yancey SW, Emmett AH, Stempel DA. Comparative effect of body mass index on response to asthma controller therapy. Allergy & Asthma Proceedings 2010 Jan-Feb;31(1):20-5.
9. Nakaji H, Petrova G, Matsumoto H, Iwata T, Ito I, Oguma T, Inoue H, Tajiri T, Nagasaki T, Kanemitsu Y, Niimi A, Mishima M. Effects of 24-week add-on treatment with ciclesonide and montelukaston small airways inflammation in asthma. Annals of Allergy, Asthma and Immunology 2013 Jan;110(3):198-203.e3.
10. Zeidler MR, Kleerup EC, Goldin JG, Kim HJ, Truong DA, Simmons MD, Sayre JW, Liu W, Elashoff R, Tashkin DP. Montelukast improves regional air-trapping due to small airways obstruction in asthma. The European Respiratory Journal 2006 Feb;27(2):307-15.
11. Fritscher LG, Rodrigues MT, Zamel N, Chapman KR. The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma. Respiratory Medicine 2009 Feb;103(2):296-300.
12. Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, Knorr B, Noonan G. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatric Pulmonology 2009 Jun;44(6):568-79.
13. Law SWY, Wong AYS, Anand S, Wong ICK, Chan EW. Neuropsychiatric events associated with leukotriene-modifying agents: a systematic review. Drug Safety 2018 Mar;41(3):253-65.
14. Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, Knorr B. Analysis of behavior-related adverse experiences in clinical trials of montelukast. The Journal of Allergy and Clinical Immunology 2009 Oct;124(4):699-706.e8.
15. Lu CY, Zhang F, Lakoma MD, Butler MG, Fung V, Larkin EK, Kharbanda EO, Vollmer WM, Lieu T, Soumerai SB, Wu AC. Asthma treatments and mental health visits after a Food and Drug Administration label change for leukotriene inhibitors. Clinical Therapeutics 2015 Jun;37(6):1280-91.
16. Bygdell M, Brunlöf G, Wallerstedt SM, Kindblom JM. Psychiatric adverse drug reactions reported during a 10-year period in the Swedish pediatric population. Pharmacoepidemiology and Drug Safety 2012 Jan;21(1):79-86.
17. Aldea Perona A, García-Sáiz M, Sanz Álvarez E. Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase(®). Drug Safety 2016 Jan;39(1):69-78.
18. Marchand MS, Jonville-Béra AP, Autret-Leca E; Association française des centres régionaux de pharmacovigilance. Troubles psychiatriques associés au montélukast: données de la base nationale de pharmacovigilance [Psychiatric disorders associated with montelukast: data from the National Pharmacovigilance Database]. Archives Pédiatrie 2013 Mar;20(3):269-73.
19. Cereza G, Doladé NG, Laporte JR. Nightmares induced by montelukast in children and adults. The European Respiratory Journal 2012 Dec;40(6):1574-5.
20. Aagaard L, Hansen EH. Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011. International Journal of Clinical Pharmacy 2014 Dec;36(6):1222-9.
21. Jick H, Hagberg KW, Egger P. Rate of suicide in patients taking montelukast. Pharmacotherapy 2009 Feb;29(2):165-6.
22. Schumock GT, Stayner LT, Valuck RJ, Joo MJ, Gibbons RD, Lee TA. Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case–control study. Journal of Allergy and Clinical Immunology 2012 Aug;130(2):368-75.
23. Chen VC, Wang TN, Liao YT, Lin TC, Stewart R, Lee CT. Asthma and self-harm: a population-based cohort study in Taiwan. Journal of Psychosomatic Research 2014 Dec;77(6):462-7.
24. Ali MM, O’Brien CE, Cleves MA, Martin BC. Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: a matched nested case–control study. Pharmacoepidemiology and Drug Safety 2015 Feb;24(4):435-45.
25. Schumock GT, Gibbons RD, Lee TA, Joo MJ, Valuck RJ, Stayner LT. Relationship between leukotriene-modifying agent prescriptions dispensed and rate of suicide deaths by county in the US. Drug, Healthcare and Patient Safety 2011;3:47-52.
26. Glockler-Lauf SD, Finkelstein Y, Zhu J, Feldman LY, To T. Montelukast and neuropsychiatric events in children with asthma: a nested case–control study. The Journal of Pediatrics 2019 Jun;209:176-82.e4.
27. U.S. Food and Drug Administration. September 27, 2019: meeting of the Pediatric and Drug Safety and Risk Management Committees. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-27-2019-meeting-pediatric-and-drug-safety-and-risk-management-committees-09272019-09272019 Accessed 2020 Jul 30.
28. U.S. Food and Drug Administration. FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. Risks may include suicidal thoughts or actions. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug Accessed 2020 Jul 30.
29. Chen F, Ghosh A, Lin J, Zhang C, Pan Y, Thakur A, Singh K, Hong H, Tang S. 5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer’ disease. Brain, Behavior, and Immunity 2020 Aug;88:844-55.
30. Ministry of Health of the Russian Federation. Bronchial asthma. Federal clinical guidelines. ICD 10: J. 45, J. 46. Year of approval (frequency of revision): 2019 (revised every 3 years). Available from: https://spulmo.ru/upload/kr_bronhastma_2019.pdf Accessed 2020 Jul 30. (In Russian).
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]